Molecular determinants of blood-brain barrier permeation

Therapeutic Delivery

Volumn 6, Issue 8, 2015, Pages 961-971

  Geldenhuys, Werner J ^a   Mohammad, Afroz S ^b   Adkins, Chris E ^b   Lockman, Paul R ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

high throughput; in silico; logPS; nutrient transporters; virtual screening

Indexed keywords

BLOOD BRAIN BARRIER; CELL CULTURE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; HUMAN; IN VITRO STUDY; MOLECULAR BIOLOGY; NONHUMAN; NUTRIENT; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ANALYSIS; PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; PERMEABILITY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; PERMEABILITY;

EID: 84945580924     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.32     Document Type: Review

References (90)

1. Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem. Neurosci. 3(1), 50-68 (2012).
2. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the united states (2010-2050) estimated using the 2010 census. Neurology 80(19), 1778-1783 (2013).
3. Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46(7), 1250-1256 (2003).
4. Ortwine DF, Aliagas I. Physicochemical and dmpk in silico models: facilitating their use by medicinal chemists. Mol. Pharm. 10(4), 1153-1161 (2013).
5. Meanwell NA. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 24(9), 1420-1456 (2011).
6. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12(1-2), 54-61 (2007).
7. Hitchcock SA. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol. 12(3), 318-323 (2008).
8. Abbott NJ. Blood-brain barrier structure and function and the challenges for cns drug delivery. J. Inherit. Metabol. Dis. 36(3), 437-449 (2013).
9. Devraj K, Klinger ME, Myers RL, Mokashi A, Hawkins RA, Simpson IA. Glut-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J. Neurosci. Res. 89(12), 1913-1925 (2011).
10. Gagliardi M, Bardi G, Bifone A. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the cns. Ther. Deliv. 3(7), 875-887 (2012).
11. Boado RJ, Hui EK, Lu JZ, Pardridge WM. IGG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. Bioconjug. Chem. 24(1), 97-104 (2013).
12. Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: A historical point of view. Anat. Rec. B New Anat. 289(1), 3-8 (2006).
13. Lai CH, Kuo KH. The critical component to establish in vitro bbb model: pericyte. Brain Res. Brain Res. Rev. 50(2), 258-265 (2005).
14. Pardridge WM. Blood-brain barrier biology and methodology. J. Neurovirol. 5(6), 556-569 (1999).
15. Cohen Z, Ehret M, Maitre M, Hamel E. Ultrastructural analysis of tryptophan hydroxylase immunoreactive nerve terminals in the rat cerebral cortex and hippocampus: their associations with local blood vessels. Neuroscience 66(3), 555-569 (1995).
16. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37(1), 13-25 (2010).
17. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6(8), 591-602 (2005).
18. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1), 22-76 (2005).
19. Manda VK, Mittapalli RK, In situ WJ, Lockman PR. Chronic exposure to nicotine and saquinavir decreases endothelial notch-4 expression and disrupts blood-brain barrier integrity. J. Neurochem. 115(2), 515-525 (2010).
20. Kalvass JC, Polli JW, Bourdet DL et al. Why clinical inhibition of efflux transport at the blood-brain barrier is unlikely: The ITC evidence-based position. Clin. Pharmacol. Ther. 94(1), 80-94 (2013).
21. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem. Res. 34(12), 2067-2077 (2009).
22. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr. Neuropharmacol. 6(3), 179-192 (2008).
23. Konofagou EE. Optimization of the ultrasound-induced blood-brain barrier opening. Theranostics 2(12), 1223-1237 (2012).
24. Martin JA, Maris AS, Ehtesham M, Singer RJ. Rat model of blood-brain barrier disruption to allow targeted neurovascular therapeutics. J. Vis. Exp. 30(69), e50019 (2012).
25. Nagaraja TN, Karki K, Ewing JR, Croxen RL, Knight RA. Identification of variations in blood-brain barrier opening after cerebral ischemia by dual contrast-enhanced magnetic resonance imaging and T 1SAT measurements. Stroke 39(2), 427-432 (2008).
26. Bahadduri PM, Polli JE, Swaan PW, Ekins S. Targeting drug transporters-combining in silico and in vitro approaches to predict in vivo. Methods Mol. Biol. 637, 65-103 (2010).
27. Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR. Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. Ther. Deliv. 1(6), 775-784 (2010).
28. In situ WJ, Allen DD. The blood-brain barrier choline transporter. Cent. Nerv. Syst. Agents Med. Chem. 12(2), 95-99 (2012).
29. In situ WJ, Allen DD, Bloomquist JR. Novel models for assessing blood-brain barrier drug permeation. Expert Opin. Drug Metabol. Toxicol. 8(6), 647-653 (2012).
30. Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am. J. Physiol. Heart Circ. Physiol. 279(3), H1022-H1028 (2000).
31. Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58(6), 2584-608 (2015).
32. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx 2(1), 15-26 (2005).
33. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 44(6), 923-930 (2001).
34. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41(7), 1007-1010 (1998).
35. Fischer H, Kansy M, Avdeef A, Senner F. Permeation of permanently positive charged molecules through artificial membranes-influence of physico-chemical properties. Eur. J. Pharm. Sci. 31(1), 32-42 (2007).
36. Wuest DM, Wing AM, Lee KH. Membrane configuration optimization for a murine in vitro blood-brain barrier model. J. Neurosci. Methods 212(2), 211-221 (2013).
37. Hellinger E, Veszelka S, Toth AE et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCKMDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur. J. Pharm. Biopharm. 82(2), 340-351 (2012).
38. Kamiichi A, Furihata T, Kishida S et al. Establishment of a new conditionally immortalized cell line from human brain microvascular endothelial cells: A promising tool for human blood-brain barrier studies. Brain Res. 1488, 113-122 (2012).
39. Roux F, Couraud PO. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell. Mol. Neurobiol. 25(1), 41-58 (2005).
40. Weksler B, Romero IA, Couraud PO. The HCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10(1), 16 (2013).
41. Mateus A, Matsson P, Artursson P. A high-throughput cellbased method to predict the unbound drug fraction in the brain. J. Med. Chem. 57(7), 3005-3010 (2014).
42. Mateus A, Matsson P, Artursson P. Rapid measurement of intracellular unbound drug concentrations. Mol. Pharm. 10(6), 2467-2478 (2013).
43. Andersson O, Hansen SH, Hellman K et al. The grasshopper: A novel model for assessing vertebrate brain uptake. J. Pharmacol. Exp. Ther. 346(2), 211-218 (2013).
44. Nielsen PA, Andersson O, Hansen SH, Simonsen KB, Andersson G. Models for predicting blood-brain barrier permeation. Drug Discov. Today 16(11-12), 472-475 (2011).
45. Watanabe K, Nishimura Y, Nomoto T et al. In vivo assessment of the permeability of the blood-brain barrier and blood-retinal barrier to fluorescent indoline derivatives in zebrafish. BMC Neurosci. 13, 101 (2012).
46. Jeong JY, Kwon HB, Ahn JC et al. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res. Bull. 75(5), 619-628 (2008).
47. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247(3 Pt 2), H484-H493 (1984).
48. Suenderhauf C, Hammann F, Huwyler J. Computational prediction of blood-brain barrier permeability using decision tree induction. Molecules 17(9), 10429-10445 (2012).
49. Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov. Today 9(9), 392-393 (2004).
50. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8(20), 927-933 (2003).
51. Tewes BJ, Galla HJ. Lipid polarity in brain capillary endothelial cells. Endothelium 8(3), 207-220 (2001).
52. Nitz T, Eisenblatter T, Psathaki K, Galla HJ. Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. Brain Res. 981(1-2), 30-40 (2003).
53. Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 1(6), 435-449 (2010).
54. Hawkins PC, Nicholls A. Conformer generation with omega: learning from the data set and the analysis of failures. J. Chem. Inform. Model. 52(11), 2919-2936 (2012).
55. Loryan I, Sinha V, Mackie C et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol. Pharm. 12(2), 520-532 (2014).
56. Wager TT, Chandrasekaran RY, Hou X et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 1(6), 420-434 (2010).
57. Allen DD, Smith QR. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76(4), 1032-1041 (2001).
58. Gratton JA, Abraham MH, Bradbury MW, Chadha HS. Molecular factors influencing drug transfer across the blood-brain barrier. J. Pharm. Pharmaol. 49(12), 1211-1216 (1997).
59. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32(1), 132-139 (2004).
60. Dagenais C, Avdeef A, Tsinman O, Dudley A, Beliveau R. P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo pampa model. Eur. J. Pharm. Sci. 38(2), 121-137 (2009).
61. Ooms F, Weber P, Carrupt PA, Testa B. A simple model to predict blood-brain barrier permeation from 3D molecular fields. Biochim. Biophys. Acta 1587(2-3), 118-125 (2002).
62. Crivori P, Cruciani G, Carrupt PA, Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43(11), 2204-2216 (2000).
63. Luco JM. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J. Chem. Inform. Comput. Sci. 39(2), 396-404 (1999).
64. Hutter MC. Prediction of blood-brain barrier permeation using quantum chemically derived information. J. Comput. Aid. Mol. Dis. 17(7), 415-433 (2003).
65. Keseru GM, Molnar L. High-throughput prediction of blood-brain partitioning: A thermodynamic approach. J. Chem. Inform. Comput. Sci. 41(1), 120-128 (2001).
66. Lobell M, Molnar L, Keseru GM. Recent advances in the prediction of blood-brain partitioning from molecular structure. J. Pharm. Sci. 92(2), 360-370 (2003).
67. Ma XL, Chen C, Yang J. Predictive model of blood-brain barrier penetration of organic compounds. Acta Pharmacol. Sin. 26(4), 500-512 (2005).
68. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88(8), 815-821 (1999).
69. Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, Butina D. Correlation and prediction of a large blood-brain distribution data set-an lfer study. Eur. J. Med. Chem. 36(9), 719-730 (2001).
70. Garg P, Verma J. In silico prediction of blood brain barrier permeability: an artificial neural network model. J. Chem. Inform. Model. 46(1), 289-297 (2006).
71. Wu ZY, Pan J, Yuan Y, Hui AL, Yang Y, Zhou A. Comparison of prediction models for blood brain barrier permeability and analysis of the molecular descriptors. Pharmazie 67(7), 628-634 (2012).
72. Lanevskij K, Japertas P, Didziapetris R. Improving the prediction of drug disposition in the brain. Expert Opin. Drug Metabol. Toxicol. 9(4), 473-486 (2013).
73. Fan Y, Unwalla R, Denny RA et al. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches. J. Chem. Inform. Model. 50(6), 1123-1133 (2010).
74. Liu R, Sun H, So SS. Development of quantitative structureproperty relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J. Chem. Inform. Comput. Sci. 41(6), 1623-1632 (2001).
75. Klon AE, Lowrie JF, Diller DJ. Improved naive bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J. Chem. Inform. Model. 46(5), 1945-1956 (2006).
76. Li H, Yap CW, Ung CY, Xue Y, Cao ZW, Chen YZ. Effect of selection of molecular descriptors on the prediction of blood-brain barrier penetrating and nonpenetrating agents by statistical learning methods. J. Chem. Inform. Model. 45(5), 1376-1384 (2005).
77. Rishton GM, Labonte K, Williams AJ, Kassam K, Kolovanov E. Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr. Opin. Drug Discov. Dev. 9(3), 303-313 (2006).
78. Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR. Exploiting nutrient transproters at the blood-brain barrier to improve brain distribution of small molecules. Ther. Deliv. 1(6), 775-784 (2011).
79. Peura L, Malmioja K, Huttunen K et al. Design, synthesis and brain uptake of lat1-targeted amino acid prodrugs of dopamine. Pharm. Res. 30(10), 2523-2537 (2013).
80. Peura L, Malmioja K, Laine K et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol. Pharm. 8(5), 1857-1866 (2011).
81. Dickens D, Webb SD, Antonyuk S et al. Transport of gabapentin by lat1 (slc7a5). Biochem. Pharmacol. 85(11), 1672-1683 (2013).
82. Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood-brain barrier and brain drug delivery. J. Nanosci. Nanotechnol. 6(9-10), 2712-2735 (2006).
83. Allen DD, Lockman PR. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci. 73(13), 1609-1615 (2003).
84. Zheng G, Zhang Z, Lockman PR et al. Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(11), 3208-3210 (2010).
85. In situ WJ, Manda VK, Mittapalli RK et al. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 20(3), 870-877 (2010).
86. Zhang Z, Lockman PR, Mittapalli RK, Allen DD, Dwoskin LP, Crooks PA. Bis-pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 18(20), 5622-5625 (2008).
87. Lockman PR, Manda VK, Geldenhuys WJ et al. Carriermediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrier. J. Pharmacol. Exp. Ther. 324(1), 244-250 (2008).
88. Geldenhuys WJ, Lockman PR, Nguyen TH et al. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg. Med. Chem. 13(13), 4253-4261 (2005).
89. Geldenhuys WJ, Lockman PR, Mcafee JH, Fitzpatrick KT, Van Der Schyf CJ, Allen DD. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett. 14(12), 3085-3092 (2004).
90. Ekins S, Tropsha A. A turning point for blood-brain barrier modeling. Pharm. Res. 26(5), 1283-1284 (2009).